Compare EQIX & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EQIX | VRTX |
|---|---|---|
| Founded | 1998 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | EDP Services |
| Sector | Real Estate | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.0B | 115.7B |
| IPO Year | 2000 | 2006 |
| Metric | EQIX | VRTX |
|---|---|---|
| Price | $1,079.14 | $453.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 24 | 29 |
| Target Price | ★ $1,076.87 | $539.69 |
| AVG Volume (30 Days) | 483.2K | ★ 999.4K |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | 61.88 | ★ 836.54 |
| EPS | ★ 4.20 | 4.02 |
| Revenue | ★ $5,998,545,000.00 | $2,488,652,000.00 |
| Revenue This Year | $12.35 | $10.79 |
| Revenue Next Year | $8.88 | $10.47 |
| P/E Ratio | $258.06 | ★ $111.52 |
| Revenue Growth | 7.85 | ★ 46.20 |
| 52 Week Low | $710.52 | $362.50 |
| 52 Week High | $1,128.68 | $509.98 |
| Indicator | EQIX | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.50 | 61.97 |
| Support Level | $1,045.00 | $449.40 |
| Resistance Level | $1,097.44 | $464.15 |
| Average True Range (ATR) | 24.54 | 9.90 |
| MACD | -5.65 | 3.55 |
| Stochastic Oscillator | 43.99 | 99.51 |
Equinix is one of the leading providers of cloud- and carrier-neutral data centers, offering colocation and interconnection services to hyperscalers and businesses. Equinix operates 270 properties in 77 metropolitan areas across 36 countries, serving over 10,000 customers. About 70% of Equinix's revenue comes from renting physical space, which allows hyperscalers and other clients to store servers, data storage, and networking equipment. The other 30% of revenue is generated primarily through interconnection services (20%) and other managed services (10%).
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.